TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy

"TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy" published on 28 Mar 2025 by National Comprehensive Cancer Network.

Authors

Institutions

Publication Details

Journal
Journal of the National Comprehensive Cancer Network
Published
2025-03-28
DOI
https://doi.org/10.6004/jnccn.2024.7252
Citations
1
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
1.05
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy

Lea Dutta, Antonio González-Martı́n, Chinyere E. Okpara, Alexandra Léary et al.
1 citations
Journal of the National Comprehensive Cancer Network
Cancer Immunotherapy and Biomarkers
1.05
article

TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy

Lea Dutta, Antonio González-Martı́n, Chinyere E. Okpara, Alexandra Léary, Bradley R. Corr, Xiaohua Wu, Helen J MacKay, Domenica Lorusso, Ramez N. Eskander, Jodi A. McKenzie, Isabelle Laure Ray-Coquard, Jung‐Yun Lee, Vicky Makker, Kosei Hasegawa, Tianle Hu, Mansoor Mirza, Ana Oaknin
article en
1 citations

Abstract

No abstract available for this paper.

Journal of the National Comprehensive Cancer NetworkVol. 23(3.5)
Université Claude Bernard Lyon 1 (FR), Sunnybrook Health Science Centre (CA), Memorial Sloan Kettering Cancer Center (US), Humanitas University (IT), University of Toronto (CA), Yonsei University (KR), Cornell University (US), Severance Hospital (KR), Institut Gustave Roussy (FR), Rigshospitalet (DK), University of California San Diego (US), Fudan University Shanghai Cancer Center (CN), Centre Léon Bérard (FR), Vall d'Hebron Hospital Universitari (ES), Clinica Universidad de Navarra (ES), Eisai (United Kingdom) (GB), Eisai (United States) (US), Vall d'Hebron Institute of Oncology (ES), University of Colorado Anschutz Medical Campus (US), Saitama Medical University (JP), University of Colorado Denver (US)
Good health and well-being
Openalex Percentile: Top 24%
Cancer Immunotherapy and Biomarkers
1.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.